Cardiac Assist Devices Market by Type (Extracorporeal Membrane Oxygenation, Intra-Aortic Balloon Pump (IABP), Total Artificial Hearts (TAH)), Modality (Implantable, Transcutaneous), End User - Global Forecast 2024-2030

[187 Pages Report] The Cardiac Assist Devices Market size was estimated at USD 1.46 billion in 2023 and expected to reach USD 1.55 billion in 2024, at a CAGR 6.51% to reach USD 2.28 billion by 2030.

Cardiac assist devices (CADs) are sophisticated medical devices designed to support and augment the pumping function of the heart in patients with heart failure or other heart-related conditions. They play a critical role in managing end-stage heart failure patients, providing a bridge to heart transplantation, serving as a destination therapy, or supporting the heart during or after surgeries. The increase in the prevalence of cardiovascular diseases worldwide, attributable to sedentary lifestyles, aging populations, and the rise in hypertension and diabetes, has surged the need for cardiac assist devices. Additionally, the expanding global awareness about the available advanced cardiac support options and the growing healthcare expenditures in emerging economies are also contributing to the market growth. Moreover, the risks and complications associated with device implantation, such as infections, bleeding, and device malfunction, pose significant challenges to the growth of the cardiac assist devices market. Furthermore, technological advancements that improve the efficacy and safety of cardiac assist devices that broaden their acceptance among healthcare providers and patients are expected to create opportunities for market growth.

The intra-aortic balloon pump is one of the simplest forms of cardiac assist devices. It involves a balloon that is inserted into the aorta and timed to inflate and deflate in sync with the cardiac cycle. This action helps to increase myocardial oxygen perfusion while simultaneously decreasing the workload of the heart. Ventricular assist devices are mechanical pumps designed to support cardiac function and blood flow in patients with weakened hearts. Left ventricular assist devices (LVADs) support the left ventricle, which pumps oxygenated blood to the body. LVADs are the most common type of VAD used, often serving as a bridge to transplant or as destination therapy. Right ventricular assist devices (RVADs) support the right ventricle, which pumps deoxygenated blood to the lungs. These are less commonly used than LVADs and are often employed temporarily. The total artificial heart is a complete replacement for the heart. This device is typically used for patients with end-stage heart failure affecting both ventricles where other treatments have failed and who are awaiting a heart transplant. It takes over the function of both the left and right ventricles, providing a temporary solution until a donor heart becomes available. An extracorporeal membrane oxygenation is a form of heart-lung bypass machine used in critical care situations. ECMO provides both cardiac and respiratory support by oxygenating the patient's blood outside the body, allowing the heart and lungs to rest and recover during acute episodes of failure.

Ambulatory surgical centers (ASCs) represent a rapidly growing sector for the deployment of cardiac assist devices. These facilities offer a convenient, cost-effective alternative for certain cardiac procedures that don't require a lengthy hospital stay. Utilization of cardiac assist devices in ASCs is typically associated with outpatient procedures or short-term post-operative care, focusing on efficiency, patient safety, and quality of care. The increasing adoption of minimally invasive techniques in these settings amplifies the demand for advanced, portable, and less intrusive cardiac assist devices. Hospitals, encompassing both general and specialty clinics, remain the primary end users for cardiac assist devices. This sector includes large tertiary care hospitals and specialized cardiac centers that handle a wide spectrum of cardiac conditions requiring support from cardiac assist devices. The use of these devices in hospitals covers both acute and chronic heart conditions, ranging from intra-aortic balloon pumps (IABPs) for temporary support during high-risk cardiology procedures to ventricular assist devices (VADs) for longer-term support in heart failure patients. Hospitals are pivotal in driving advancements in cardiac care, often leading to the adoption of cutting-edge technologies in cardiac assist devices. Specialty clinics focus on specific areas within the cardiac care spectrum, offering targeted treatments and services that may not be available in general hospitals. These clinics play a crucial role in the early adoption and specialized application of cardiac assist devices, particularly for patient populations with specific needs. Specialty clinics often collaborate with larger institutions for comprehensive care, serving as critical points for the deployment of cardiac assist devices for both diagnostic and therapeutic purposes. Their specialized nature fosters a high level of expertise in device management and patient care.

The Americas represents a highly developing landscape for the global market for cardiac assist devices due to the high prevalence of cardiovascular diseases, robust healthcare infrastructure, and significant investments in research and development. The region benefits from the presence of key market players that focus on innovation and launching technologically advanced products. Medical device regulation policies in the US are also conducive to the rapid adoption of new technologies. Moreover, the increasing aging population and favorable reimbursement scenarios further stimulate market growth. The APAC region is witnessing growth in the cardiac assist devices market, attributed mainly to the rising incidence of cardiac diseases, improving healthcare infrastructure, and increasing healthcare expenditure. Countries including China and India, with their vast population bases and growing middle-class, present significant opportunities for market expansion. The region also benefits from government initiatives aimed at improving healthcare access. The EMEA region showcases a strong landscape for cardiac assist devices due to its advanced healthcare system, high healthcare expenditure, and increasing prevalence of cardiovascular diseases. Countries such as Germany, the UK, and France are at the forefront, driven by favorable healthcare policies, high awareness levels, and well-established healthcare infrastructure. The Middle East is rapidly growing due to increasing healthcare investments and a growing focus on healthcare modernization.

The FPNV Positioning Matrix is pivotal in evaluating the Cardiac Assist Devices Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cardiac Assist Devices Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

• Supira Medical's Next Generation Percutaneous Ventricular Assist Device (pVAD) System to be Highlighted in a Live Case and Multiple Sessions at the Upcoming TCT 2023 Conference

  Supira Medical, Inc. launched a percutaneous ventricular assist device (pVAD), including an anticipated live case demonstration. This inclusion underscores the system's pioneering approach, characterized by its minimal invasiveness and superior continuous flow capabilities, which are poised to revolutionize hemodynamic support for both practitioners and patients alike. [Published On: 2023-10-20]

• Abbott Receives FDA Approval for World's First Dual Chamber Leadless Pacemaker

  Abbott has received approval from the U.S. Food and Drug Administration (FDA) for its groundbreaking AVEIR DR leadless pacemaker system, marking a significant milestone in cardiac care technology. This innovative system, which is the first of its kind to offer dual chamber leadless pacing, is designed to address the needs of patients experiencing abnormal or slow heart rhythms by providing pacing to both the right atrium and right ventricle. This approval is poised to benefit millions of Americans, as over 80% of pacemaker users require dual-chamber pacing. The AVEIR DR system represents a leap forward in medical technology, providing an expanded range of leadless pacing options and enhancing the treatment capabilities for individuals with heart rhythm disorders. [Published On: 2023-07-05]

• UltraLinQ to Launch New Cardiac Monitoring Product at Arab Health

  Ultralinq announced the launch of ITS latest product in cardiac monitoring at Arab Health. This innovative solution offers advanced and comprehensive Holter ECG monitoring for improved patient care. The state-of-the-art Holter ECG monitor can record and store up to 14 days of high-quality ECG data. Its user-friendly design simplifies the patient experience and reduces the time spent during clinic appointments. [Published On: 2023-01-31]

The report delves into recent significant developments in the Cardiac Assist Devices Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AlivCor Inc., Bardy Diagnostics, Inc., Berlin Heart GmbH, BiVACOR Inc., Boston Scientific Corporation, Cardiac Insight, Inc., Cardiobridge GmbH, CorInnova, Inc., CorWave SA, GE HealthCare Technologies Inc., Getinge AB, Hill-Rom Holdings, Inc., Jarvik Heart Inc., Koninklijke Philips N.V., LivaNova PLC, Medtronic PLC, OSI Systems, Inc., Supira Medical, Teleflex Incorporated, Terumo Corporation, and Xenios AG.

This research report categorizes the Cardiac Assist Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Type
  • Extracorporeal Membrane Oxygenation
  • Intra-Aortic Balloon Pump (IABP)
  • Total Artificial Hearts (TAH)
  • Ventricular Assist Devices (VADs)
    • Left Ventricular Assist Devices (LVADs)
    • Right Ventricular Assist Devices (RVADs)
• Modality
  • Implantable
  • Transcutaneous
• End User
  • Ambulatory Surgical Centers
  • Hospitals & Specialty Clinics

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

1. What is the market size and forecast of the Cardiac Assist Devices Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cardiac Assist Devices Market?
3. What are the technology trends and regulatory frameworks in the Cardiac Assist Devices Market?
4. What is the market share of the leading vendors in the Cardiac Assist Devices Market?
5. Which modes and strategic moves are suitable for entering the Cardiac Assist Devices Market?